Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials-Reference-Cited by-同舟云学术

Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials

Published:2022-02-10 Issue:4 Volume:31 Page:401-413
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Cammarota Antonella¹²^ORCID,Zanuso Valentina¹²^ORCID,D’Alessio Antonio¹³^ORCID,Pressiani Tiziana²^ORCID,Personeni Nicola¹²^ORCID,Rimassa Lorenza¹²^ORCID

Affiliation:

1. Department of Biomedical Sciences, Humanitas University, Milan, Italy

2. Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy

3. Department of Surgery & Cancer, Imperial College London, Hammersmith Hospitalc, London, UK

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2022.2032641

Reference100 articles.

1. World Health Organization. Liver; [cited 2021 Oct 26].